Literature DB >> 27160479

Bortezomib improves survival in rare myeloma.

Vicki Brower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27160479     DOI： 10.1016/S1470-2045(16)30129-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Epidemiology of multiple myeloma in 17 Latin American countries: an update.

Authors:  Maria Paula Curado; Max M Oliveira; Diego R M Silva; Dyego L B Souza
Journal:  Cancer Med       Date:  2018-03-24       Impact factor: 4.452

2.  Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat.

Authors:  Tiewei Cheng; Kendall Kiser; Leslie Grasse; Lakesla Iles; Geoffrey Bartholomeusz; Felipe Samaniego; Robert Z Orlowski; Joya Chandra
Journal:  Cancer Drug Resist       Date:  2021-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.